Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma
Novartis’ CAR T therapy Kymriah has shown promise for the treatment of relapsed or refractory follicular lymphoma – the second most common form of non-Hodgkin lymphoma (NHL).
Primary analysis from the Phase II ELARA trial includes 97 patients who were infused with Kymriah (tisagenlecleucel) and evaluated for safety. Of those patients, 94 were evaluable for efficacy with a median follow-up of 11 months.
The CAR T therapy led to responses for the majority of treated patients, with 66% achieving a complete response (CR) and an overall response rate of 86%.
Novartis added that the response rates were consistent across high-risk subgroups in the ELARA analysis.
In addition, median duration of response (DoR) in all responders, progression free survival (PFS) and overall survival (OS) had not been reached at the time of the primary analysis.
However, estimated DoR in patients with CR and PFS rates at six months were 94% and 76%, respectively.
Read more: https://www.pharmatimes.com/news/novartis_car_t_therapy_kymriah_shows_promise_in_follicular_lymphoma_1371143
Primary analysis from the Phase II ELARA trial includes 97 patients who were infused with Kymriah (tisagenlecleucel) and evaluated for safety. Of those patients, 94 were evaluable for efficacy with a median follow-up of 11 months.
The CAR T therapy led to responses for the majority of treated patients, with 66% achieving a complete response (CR) and an overall response rate of 86%.
Novartis added that the response rates were consistent across high-risk subgroups in the ELARA analysis.
In addition, median duration of response (DoR) in all responders, progression free survival (PFS) and overall survival (OS) had not been reached at the time of the primary analysis.
However, estimated DoR in patients with CR and PFS rates at six months were 94% and 76%, respectively.
Read more: https://www.pharmatimes.com/news/novartis_car_t_therapy_kymriah_shows_promise_in_follicular_lymphoma_1371143
